GlobeNewswire

FDA approves Xolair® (omalizumab) for adults with nasal polyps

Share
  • Xolair is the first biologic for the treatment of nasal polyps that targets and blocks immunoglobulin E (IgE), a key driver of inflammation
  • Xolair is now FDA-approved across three diseases and in two formulations, continuing to build on the medicine’s 17 years of patient experience since its initial approval for allergic asthma


Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this approval, Xolair is now the first biologic for the treatment of nasal polyps that targets and blocks immunoglobulin E (IgE), a key driver of inflammation.

“With Xolair, we observed significantly reduced nasal polyps and congestion symptoms in adults who had nasal polyps in two pivotal Phase III studies,” said Joseph Han, M.D., Chief of the Division of Rhinology and the Division of Allergy at Eastern Virginia Medical School and study investigator of the POLYP 1 and POLYP 2 trials. “Xolair provides a new option for treating these patients, who often have other respiratory and allergic conditions that may further worsen symptoms.”

The FDA’s approval is based on results from the Phase III POLYP 1 and POLYP 2 trials. Both trials showed that adult patients with nasal polyps who had an inadequate response to nasal corticosteroids and received Xolair had statistically significant greater improvement from baseline at Week 24 in Nasal Polyp Score (NPS) and weekly average Nasal Congestion Score (NCS) than patients who received placebo.1 The greater improvements in NPS and NCS in the Xolair group compared to the placebo group were observed as early as the first assessment at Week 4 in both studies. All patients received background nasal mometasone therapy during both the treatment period and a five-week run-in period. The safety profile in POLYP 1 and POLYP 2 was consistent with the established safety profile for Xolair.

“With today’s approval, people living with nasal polyps now have a treatment option that targets IgE, an underlying driver of various allergic conditions,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We are committed to understanding the full potential of Xolair across the spectrum of allergic diseases and are excited to provide this important treatment for people living with nasal polyps.”

Xolair is an injectable biologic medicine that is also FDA-approved for the treatment of moderate to severe persistent allergic asthma in people 6 years of age or older whose asthma symptoms are not controlled by inhaled corticosteroids, and for chronic idiopathic urticaria (CIU) in people 12 years of age and older who continue to have hives that are not controlled by H1 antihistamines. Approximately 460,000 patients have been treated in the U.S. with Xolair since its initial approval for allergic asthma in 2003.2 In the U.S., Genentech and Novartis Pharmaceuticals Corporation work together to develop and co-promote Xolair.

About Nasal Polyps
Nasal polyps is a commonly occurring and potentially debilitating condition in adults, impacting 13 million people in the U.S.3,4 Currently, there are limited treatment options available and many patients opt for nasal surgery or systemic steroids. However, polyps may regrow over time. Nasal polyps present as noncancerous lesions on the lining of the nasal sinuses or nasal cavity associated with irritation and inflammation, which can block normal airflow.5 Nasal polyps may co-occur with other respiratory conditions, such as allergies and asthma.

About POLYP 1 and POLYP 2
In POLYP 1 and POLYP 2, the mean change from baseline at Week 24 for Xolair compared to placebo were: NPS, -1.1 versus 0.1 (95% CI: -1.6, -0.7) and -0.9 versus -0.3 (95% CI: -1.1, -0.1); NCS, -0.9 versus -0. 4 (95% CI: -0.8, -0.3) and -0.7 versus -0.2 (95% CI: -0.8, -0.2).1 POLYP 1 and POLYP 2 are the ninth and tenth Phase III trials for Xolair, respectively. Results from POLYP 1 and POLYP 2 were recently published in the Journal of Allergy and Clinical Immunology. No new or unexpected safety signals were identified in patients treated with Xolair, with over 95% of patients completing each safety arm of POLYP 1 and POLYP 2.6 The most common adverse reactions (≥3% of patients) included headache, injection site reaction, arthralgia, upper abdominal pain and dizziness.

POLYP 1 and POLYP 2 are replicate Phase III pivotal studies designed to determine the efficacy and safety of Xolair compared with placebo in adult patients with nasal polyps who had an inadequate response to nasal corticosteroids. Both trials were randomized, multicenter, double-blind and placebo-controlled. POLYP 1 involved 138 patients, and POLYP 2 involved 127 patients. The co-primary outcomes for both trials were change from baseline to Week 24 in average daily Nasal Congestion Score and Nasal Polyp Score. Patients in the studies were administered either Xolair or placebo by subcutaneous injection every two to four weeks in addition to background nasal mometasone therapy during both the treatment period and a five-week run-in period.1

About Xolair
Xolair is the only approved antibody designed to target and block immunoglobulin E (IgE). By reducing free IgE, down-regulating high-affinity IgE receptors and limiting mast cell degranulation, Xolair minimizes the release of mediators throughout the allergic inflammatory cascade.

About Roche in Immunology
The Roche Group’s immunology medicines include: Actemra®/RoActemra® (tocilizumab) for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA) and giant cell arteritis (GCA) and for the treatment of severe or life-threatening chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome (CRS); Rituxan®/MabThera® (rituximab) for rheumatoid arthritis granulomatosis with polyangiitis and microscopic polyangiitis and for pemphigus vulgaris (PV); Xolair® (omalizumab) for allergic asthma and chronic idiopathic urticaria (CIU); Pulmozyme® (dornase alfa) for cystic fibrosis; and Esbriet® (pirfenidone) for idiopathic pulmonary fibrosis (IPF). Roche has more than 15 investigational medicines in clinical development for immunological diseases that include asthma, autoimmune diseases, rheumatoid arthritis, ulcerative colitis and Crohn's disease.

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Xolair® Full Prescribing Information. Genentech, Inc.; November 2020.
[2] Data on file. Genentech, Inc.
[3] United States Census Bureau. QuickFacts. Census Bureau population estimates (2018). Accessed October 2020. https://www.census.gov/quickfacts/fact/table/US/PST045218
[4] Stevens WW, Schleimer RP, Kern RC. Chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2016;4(4):565572.
[5] Mayo Clinic. Nasal polyps. Accessed October 2020. https://www.mayoclinic.org/diseases-conditions/nasal-polyps/symptoms-causes/syc-20351888.
[6] Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: two randomized phase III trials. J Allergy and Clin Immunol. 2020; 146(3):595-605. doi: 10.1016/j.jaci.2020.05.032

Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Dr. Nicolas Dunant
Phone: +41 61 687 05 17

Patrick Barth
Phone: +41 61 688 44 86
Dr. Daniel Grotzky
Phone: +41 61 688 31 10

Karsten Kleine
Phone: +41 61 682 28 31
Nina Mählitz
Phone: +41 79 327 54 74

Nathalie Meetz
Phone: +41 61 687 43 05
Dr. Barbara von Schnurbein
Phone: +41 61 687 89 67


Roche Investor Relations
Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail: karl.mahler@roche.com

Jon Kaspar Bayard
Phone: +41 61 68-83894
e-mail: jon_kaspar.bayard@roche.com
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com

Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com
Investor Relations North America
Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com
Dr. Lisa Tuomi
Phone: +1 650 467 8737
e-mail: tuomi.lisa@gene.com

Attachment


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

SEK TENDER OPERATION ANNOUNCEMENT FOR ONWARD LENDING27.1.2021 16:20:00 CETPress release

Bid date, 2021-01-29Bid Submission Date2021-01-29Bid times10.30-11.00 (CET/CEST) on the Bid dateOffered Amount50 billion SEKMaximum Permitted Bid Volume12.5 billion SEK from an individual bidderSettlement Date2021-02-02Minimum Permitted Bid Volume10 million SEK per bidFinal Repayment Date2025-02-03Maximum Allocation25 per cent of Offered AmountAllocation TimeNot later than 11.30 (CET/CEST) on the Bid dateRepayment Date2022-02-02Option Repayment Date 12023-02-02Option Repayment Date 22024-02-02Interest rateThe Riksbank´s applicable repo rateAdditional interest rate0.10 per centConfirmation of bids to e-maileol@riksbank.se Stockholm, 2021-01-27 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.

Hexagon Purus selected by Talgo for first zero-emission hydrogen train in Spain27.1.2021 16:00:00 CETPress release

Hexagon Purus has received an order to deliver high pressure cylinders to Talgo, S.A., a leading manufacturer of intercity, standard and high speed passenger trains, for its first hydrogen prototype train. The Talgo Vittal-One train will be built and deployed in Spain and will serve as a testbed for how hydrogen technologies could be implemented in the Iberian Southwest. “There are more than 10,000 diesel trains in operation across Europe that will need to be replaced over the next 15 years. For distances between 400-800 km, hydrogen-powered trains are a smart solution to reduce local emissions without incurring the high cost of electrifying the tracks,” says Michael Kleschinski, Executive Vice President of Hexagon Purus. “We are excited to help develop the solutions needed for this ground-breaking move in public transit.” “Green hydrogen is no longer the future, it is a reality,” says Mr. Emilio García. Innovation Director at TALGO. “The start-up of hydrogen trains such as Talgo’s Vit

Property Carriers Beat Fraud with New Prior Loss Images in Verisk’s ISO ClaimSearch®27.1.2021 15:45:00 CETPress release

Jersey City, N.J., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Verisk (Nasdaq:VRSK) announced that ISO ClaimSearch, the world’s largest database of property and casualty insurance (P&C) claims, has enhanced its robust claim intelligence platform by adding prior loss image matching. This automates previously laborious processes and significantly bolsters fraud protection. Millions of property images have been added to the system, which contains over 1.5 billion claim records and receives ongoing contributions from more than 90% of P&C insurers. Verisk created this enhancement – available at no cost to participants -- by tapping into participant-authorized claim images from its Xactware property estimation system. How ISO ClaimSearch works: As adjusters review ISO ClaimSearch match reports, a simple on-screen camera icon easily identifies prior claims containing photos.Prior loss images may reveal pre-existing damage, or the same damage being claimed again.Image forensics expose anomalies such as

Virgin Hyperloop Unveils Passenger Experience Vision27.1.2021 15:00:00 CETPress release

Groundbreaking design shows end-to-end passenger experience for the 21st century LOS ANGELES, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Just months after their first passenger testing, Virgin Hyperloop today unveiled its vision for the future hyperloop experience. The newly-released concept video takes the viewer step-by-step through a hyperloop journey, from arriving at the portal to boarding the pod. “Showing the passenger experience of Virgin Hyperloop is a glimpse of the future, following the success three months ago when people rode in a hyperloop pod for the first time,” said Sultan Bin Sulayem, Chairman of Virgin Hyperloop and Group Chairman and CEO of DP World. “We have demonstrated the maturity of our technology. We are getting closer to commercialization of what will be the first new mass-scale transportation mode in a century.” “Designing a new mode of transportation from scratch is both an opportunity and a responsibility,” said Sara Luchian, Virgin Hyperloop’s Director of Passenge

Virgin Hyperloop Unveils Passenger Experience Vision27.1.2021 15:00:00 CETPress release

Groundbreaking design shows end-to-end passenger experience for the 21st century LOS ANGELES, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Just months after their first passenger testing, Virgin Hyperloop today unveiled its vision for the future hyperloop experience. The newly-released concept video takes the viewer step-by-step through a hyperloop journey, from arriving at the portal to boarding the pod. “Showing the passenger experience of Virgin Hyperloop is a glimpse of the future, following the success three months ago when people rode in a hyperloop pod for the first time,” said Sultan Bin Sulayem, Chairman of Virgin Hyperloop and Group Chairman and CEO of DP World. “We have demonstrated the maturity of our technology. We are getting closer to commercialization of what will be the first new mass-scale transportation mode in a century.” “Designing a new mode of transportation from scratch is both an opportunity and a responsibility,” said Sara Luchian, Virgin Hyperloop’s Director of Passenge

Golar LNG Partners LP Cash Distributions27.1.2021 15:00:00 CETPress release

Golar LNG Partners LP (“the Partnership”) (NASDAQ: GMLP) announced today that its board of directors has approved a quarterly cash distribution with respect to the quarter ended December 31, 2020 of $0.0202 per common and general partner unit. This cash distribution will be paid on February 12, 2021 to all common and general partner unitholders of record as of the close of business on February 5, 2021. As set forth in our press release dated January 13, 2021, the Partnership has entered into a merger agreement with New Fortress Energy, Inc. (“NFE”). For additional information, please see the Partnership’s definitive proxy statement which will be filed with the Securities and Exchange Commission. A cash distribution of $0.546875 per Series A preferred unit (NASDAQ: GMLPP) for the period from November 15, 2020 through February 14, 2021 has also been declared. This will be payable on February 15, 2021 to all Series A preferred unitholders of record as at February 8, 2021. Under the merger